Manu Pandey

418 total citations
25 papers, 239 citations indexed

About

Manu Pandey is a scholar working on Oncology, Immunology and Psychiatry and Mental health. According to data from OpenAlex, Manu Pandey has authored 25 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Immunology and 6 papers in Psychiatry and Mental health. Recurrent topics in Manu Pandey's work include Cancer Immunotherapy and Biomarkers (7 papers), Cancer, Stress, Anesthesia, and Immune Response (6 papers) and CAR-T cell therapy research (4 papers). Manu Pandey is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Cancer, Stress, Anesthesia, and Immune Response (6 papers) and CAR-T cell therapy research (4 papers). Manu Pandey collaborates with scholars based in United States, United Kingdom and France. Manu Pandey's co-authors include Marc S. Ernstoff, Shipra Gandhi, Mark J. Bucsek, Kristopher Attwood, Elizabeth A. Repasky, Hemn Mohammadpour, Igor Puzanov, Jeffrey Baron, Wenyan Ji and Joseph J. Drabick and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Manu Pandey

20 papers receiving 237 citations

Peers

Manu Pandey
Deborah A. Silverman United States
Michael Rassner Germany
Anthony Restaino United States
Shaul Kadosh United States
Aya Haggiagi United States
Laleh Saadat United States
Sonja Boatman United States
Joseph A. Saglimbeni United States
Adrienne I. Victor United States
Deborah A. Silverman United States
Manu Pandey
Citations per year, relative to Manu Pandey Manu Pandey (= 1×) peers Deborah A. Silverman

Countries citing papers authored by Manu Pandey

Since Specialization
Citations

This map shows the geographic impact of Manu Pandey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manu Pandey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manu Pandey more than expected).

Fields of papers citing papers by Manu Pandey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manu Pandey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manu Pandey. The network helps show where Manu Pandey may publish in the future.

Co-authorship network of co-authors of Manu Pandey

This figure shows the co-authorship network connecting the top 25 collaborators of Manu Pandey. A scholar is included among the top collaborators of Manu Pandey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manu Pandey. Manu Pandey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hassan, Ali, et al.. (2025). Plasma cell leukemia: Updates on demographics and prognostication.. Journal of Clinical Oncology. 43(16_suppl).
4.
Daneshmandi, Saeed, Yan Qi, Cameron R. MacDonald, et al.. (2024). Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies. Nature Communications. 15(1). 2803–2803. 22 indexed citations
5.
Baron, Jeffrey, Manu Pandey, Elizabeth A. Griffiths, & Eunice S. Wang. (2024). Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients. Leukemia Research Reports. 22. 100474–100474.
6.
Pandey, Manu, et al.. (2023). Impact of primary organ site of involvement by peripheral T‐cell lymphoma not otherwise specified on survival. Cancer Medicine. 12(24). 21770–21778. 2 indexed citations
7.
Hall, Spencer R., Yan D. Zhao, Manu Pandey, et al.. (2023). Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 23(5). 379–384. 3 indexed citations
8.
Pandey, Manu, Agnieszka K. Witkiewicz, Erik S. Knudsen, et al.. (2022). Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma. Cancer Research. 82(12_Supplement). CT568–CT568. 1 indexed citations
9.
Daneshmandi, Saeed, Cameron R. MacDonald, Manu Pandey, et al.. (2022). β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies. Blood. 140(Supplement 1). 8867–8869. 1 indexed citations
10.
MacDonald, Cameron R., Manu Pandey, Bonnie L. Hylander, et al.. (2021). Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice. Cellular Immunology. 361. 104285–104285. 14 indexed citations
11.
Pandey, Manu, et al.. (2021). COVID-19 crisis: Liquidity management at Canada’s largest public pension funds. Bank of Canada Research. 1 indexed citations
12.
Gandhi, Shipra, Manu Pandey, Kristopher Attwood, et al.. (2020). Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research. 27(1). 87–95. 87 indexed citations
13.
Pandey, Manu, et al.. (2020). Diffuse large B-Cell lymphoma associated with paraneoplastic Guillain–Barré syndrome: A diagnostic and therapeutic challenge. Hematology/Oncology and Stem Cell Therapy. 1 indexed citations
14.
Gandhi, Shipra, Manu Pandey, Chong Wang, et al.. (2020). Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors. Immunotherapy. 12(2). 141–149. 25 indexed citations
15.
Pandey, Manu & Marc S. Ernstoff. (2019). Mechanism of resistance to immune checkpoint inhibitors. Cancer Drug Resistance. 2(2). 178–188. 3 indexed citations
16.
Pandey, Manu, et al.. (2019). Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. OncoImmunology. 8(8). 1606639–1606639. 15 indexed citations
17.
Gandhi, Shipra, Sarabjot Pabla, Mary Nesline, et al.. (2017). Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders.. Journal of Clinical Oncology. 35(15_suppl). 11565–11565. 3 indexed citations
18.
Pandey, Manu, Shipra Gandhi, & Saby George. (2017). Heart Failure: A Paraneoplastic Manifestation of Renal Cell Carcinoma – Reversed With Pazopanib. Clinical Genitourinary Cancer. 15(5). e835–e837. 2 indexed citations
19.
Gandhi, Shipra, Manu Pandey, Katy Wang, et al.. (2017). Clinical and biochemical parameters as predictors of response to checkpoint inhibitors (CPI): A single institution experience.. Journal of Clinical Oncology. 35(15_suppl). e14590–e14590. 2 indexed citations
20.
Ernstoff, Marc S., Shipra Gandhi, Manu Pandey, et al.. (2017). Challenges faced when identifying patients for combination immunotherapy. Future Oncology. 13(18). 1607–1618. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deborah A. Silverman Breakdown of academic impact, for papers by Michael Rassner Breakdown of academic impact, for papers by Anthony Restaino Breakdown of academic impact, for papers by Shaul Kadosh Breakdown of academic impact, for papers by Aya Haggiagi Breakdown of academic impact, for papers by Laleh Saadat Breakdown of academic impact, for papers by Sonja Boatman Breakdown of academic impact, for papers by Joseph A. Saglimbeni Breakdown of academic impact, for papers by Adrienne I. Victor
Rankless by CCL
2026